You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《美股業績》Moderna(MRNA.US)季績勝預期 料今年或須打第四針
阿思達克 02-25 08:46
Moderna(MRNA.US)去年第四季扭虧爲盈,賺48.68億美元,每股盈利爲11.29美元,優於市場預期的10.17美元。收入爲72.1億美元,同樣勝預期,此前一年僅爲5.71億美元。 季內新冠疫苗銷售爲177億美元,略高於1月份時宣佈的175億美元初步數字,去年在全球合共運送8.07億劑疫苗。 Moderna認爲今年稍後將需要第4針新冠疫苗,因爲早期疫苗的保護作用減弱,相信這可能會推高下半年的銷售,預計今年疫苗銷售爲190億美元,高於此前估計的185億美元。 另外,公司表示,正在開發一種新的二價疫苗,結合應對Omicron變種病毒以及原始的新冠病毒。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account